Systematic Review on the Efficacy and Safety of Immune Checkpoint Inhibition in Renal Cell Carcinoma

References

• Sánchezgastaldo A , KempfE, GonzálezADA, DuranI. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat. Rev.60, 77 (2017).
   PubMed Web of Science ®Google Scholar
• Roulin D , DemartinesN, DormondO. ATP-competitive inhibitors of mTOR: new perspectives in the treatment of renal cell carcinoma. Biochem. Soc. Trans.39(2), 492–494 (2011).
   PubMedGoogle Scholar
• Wang DY , YeF, ZhaoS, JohnsonDB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology6(10), e1344805 (2017).
   PubMed Web of Science ®Google Scholar
• Carlo MI , VossMH, MotzerRJ. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. Nat. Rev. Urol.13(7), 420 (2016).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Taneja SS . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med.188(6), 2148–2149 (2012).
   Google Scholar
• Weinstock M , McDermottD. Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Ther. Adv. Urol.7(6), 365 (2015).
   PubMed Web of Science ®Google Scholar
• Atkins MB , ClarkJI, QuinnDI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Ann. Oncol.28(7), 1484–1494 (2017).
   PubMed Web of Science ®Google Scholar
• Asar SH , JalalpourSH, AyoubiF, RahmaniMR, RezaeianM. Prisma; preferred reporting items for systematic reviews and meta-analyses (2016). www.prisma-statement.org/.
   Google Scholar
• Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma – NEJM. N. Engl. J. Med.373(19), 1814–1823 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , RiniBI, McDermottDFet al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol.33(13), 1430–1437 (2015).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , FishmanMN, EscudierBet al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res.22(22), 5461 (2016).
   PubMed Web of Science ®Google Scholar
• Hammers H , PlimackER, InfanteJRet al. Updated results from a Phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): the CheckMate 016 study. Presented at: International Kidney Cancer Symposium.Miami, FL, USA, 4–5 November 2016.
   Google Scholar
• Gao J , KaramJA, WoodCGet al. Abstract CT083: clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma. Cancer Res.77(13 Suppl.), CT083–CT083 (2017).
   Google Scholar
• McDermott DF , InfanteJR, ChowdhurySet al. 2622 a Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC). Eur. J. Cancer51, S519–S520 (2015).
   Web of Science ®Google Scholar
• McDermott DF , AtkinsMB, MotzerRJet al. A Phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts). J. Clin. Oncol.35(6 Suppl.), 431–431 (2017).
   Web of Science ®Google Scholar
• Boersdoets CB , RaberdurlacherJE, TreisterNSet al. Mammalian target of rapamycin inhibitor-associated stomatitis. Future Oncol.9(12), 1883–1892 (2013).
   PubMed Web of Science ®Google Scholar
• Conteduca V , SantoniM, MedriMet al. Correlation of stomatitis and cutaneous toxicity with clinical outcome in patients with metastatic renal-cell carcinoma treated with everolimus. Clin. Genitourin. Cancer14(5), 426–431 (2016).
   PubMed Web of Science ®Google Scholar
• Fusumae T , KamiyaK, ChiangBet al. Synergistic effects of interferon-beta and nivolumab in oral mucosal melanoma. J. Derm.45(1), 87–90 (2017).
   PubMed Web of Science ®Google Scholar
• Cella D , GrünwaldV, NathanPet al. Quality of life in patients with advanced renal cell carcinoma treated with nivolumab versus everolimus in CheckMate 025, a randomised, Phase III clinical trial. Lancet Oncol.17(7), 994 (2016).
   PubMed Web of Science ®Google Scholar
• Sarfaty M , LeshnoM, GordonNet al. Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur. Urol.73(4), 628–634 (2017).
   PubMed Web of Science ®Google Scholar
• Yang JC , HughesM, KammulaUet al. Ipilimumab (Anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Int. J. Immunother.30(8), 825–830 (2007).
   PubMed Web of Science ®Google Scholar
• Attia P , PhanGQ, MakerAVet al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti–cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol.23(25), 6043–6053 (2005).
   PubMed Web of Science ®Google Scholar
• Ueda H , HowsonJM, EspositoLet al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature423(6939), 506–511 (2003).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB, McDermottDFet al. CheckMate 025: a randomized, open-label, Phase Ill study of nivolumab versus everolimus in advanced renal cell carcinoma (RCC). Presented at: 14^th International Kidney Cancer Symposium. Miami, FL, USA, 6–7 November 2015.
   Google Scholar
• Swart M , VerbruggeI, BeltmanJB. Combination approaches with immune-checkpoint blockade in cancer therapy. Front. Oncol.6, 233 (2016).
   PubMed Web of Science ®Google Scholar
• Eatock MM , SchätzleinA, KayeSB. Tumour vasculature as a target for anticancer therapy. Cancer Treat. Rev.26(3), 191–204 (2000).
   PubMed Web of Science ®Google Scholar
• Bouzin C , FeronO. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery. Drug Resist. Updat.10(3), 109–120 (2007).
   PubMed Web of Science ®Google Scholar
• Hato T , ZhuAX, DudaDG. Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma. Immunotherapy8(3), 299 (2016).
   PubMed Web of Science ®Google Scholar
• McDermott DF , InfanteJR, ChowdhurySet al. A Phase I/II study to assess the safety and efficacy of pazopanib (paz) and pembrolizumab (pembro) in patients (pts) with advanced renal cell carcinoma (aRCC). Eur. J. Cancer51, S519–S520 (2015).
   Web of Science ®Google Scholar
• Clinical trials database: NCT02420821. https://clinicaltrials.gov/ct2/show/NCT02420821.
   Google Scholar
• Larkin JMG , GordonMS, ThistlethwaiteFet al. Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. J. Clin. Oncol.34(15 Suppl.), doi:10.1200/JCO.2016.34.15_suppl.TPS4580 (2016).
   Google Scholar
• Clinical trials database: NCT02684006. https://clinicaltrials.gov/ct2/show/NCT02684006.
   Google Scholar
• Clinical trials database: NCT02853331. https://clinicaltrials.gov/ct2/show/NCT02853331.
   Google Scholar